Fitbit Shares Shape Up on Reports of Offer From Alphabet

The maker of wearable fitness devices has seen its stock sprint higher on the buyout news after languishing this summer near multi-year lows.

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Big Biotech Receives Some Needed Shots in the Arm

Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.

Raytheon Could Rally to the $230 Area in the Months Ahead - How to Buy It Now

Let's review the charts and indicators to see what they are showing today.

Possible M&A Surrounds These 3 Stocks

M&A activity has generally slowed.

The Cannabis Sector and Its Dot-Com Like Meltdown

Black-market vaping has made the entire cannabis group toxic.

Jim Cramer: How Iger and Benioff Let Twitter Get Away

Both are proud they dodged the Twitter bullet. But, in retrospect, was it really a bullet?

Fed Finally Gets It, Calling AT&T and Microsoft Delivers: Market Recon

A dividend hike and a big buyback authorization by Mr. Softee should produce value for shareholders.

I Have a Solution to Adobe's Growth Problem: DocuSign

The cloud stock's results weren't great, but were nothing close to the FedEx disaster.

VMware Shows New Strength, But Wait for a Dip or Retest to Buy

After a sprint higher in the IT company's shares in recent days, traders and investors might do well to wait for a temporary pullback to pick up the stock.